CIK 0001231457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- 4/A Insider Changes in Ownership
- 4 Open-market sale 10% owner sold 64,857 shares at an average $2.65 ($171,678)
- 4 Planned sale Director sold 1,730 shares at $2.60 ($4,499)
- 4 Open-market sale 10% owner sold 75,143 shares at an average $2.62 ($196,609)
- 4 Open-market sale 10% owner sold 42,818 shares at $2.09 ($89,614)
- 4 Open-market sale 10% owner sold 265,552 shares at an average $2.09 ($554,411)
- 4 Open-market sale 10% owner sold 91,630 shares at an average $2.19 ($200,278)
- 4 Grant or award Director acquired 39,541 shares (grant or award)
- 4 Grant or award Director acquired 39,541 shares (grant or award)
- 4 Grant or award Director acquired 39,541 shares (grant or award)
- 4 Grant or award Director acquired 39,541 shares (grant or award)
- 4 Grant or award President and CEO acquired 34,584 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 5,072 shares (grant or award)
- 4 Grant or award Head of Regulatory acquired 2,723 shares (grant or award)
- 4 Grant or award VP, Pharmaceutical Development acquired 15,218 shares (grant or award)
- 4 Open-market sale VP, Clinical Trial Operations sold 6,849 shares at $2.12 ($14,520)
- 4 Open-market sale General Counsel sold 5,496 shares at $2.12 ($11,652)
- 4 Open-market sale Head of Quality sold 4,961 shares at $2.12 ($10,517)
- 4 Open-market buy Director bought 6,250 shares
- 4 Open-market buy Director bought 6,250 shares
Page 5 of 10 · 190 filings